Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenobarbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 known ✓ | P45452 | 2/20 | 0.51 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.49 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.46 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.46 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.46 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.46 |
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.46 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.46 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.46 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.46 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.46 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.46 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 6/20 | 0.77 |
| ▸ | MMP9 | P14780 | 6/20 | 0.77 |
| ▸ | MMP3 | P08254 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenobarbital SCHEMBL2592325 | 0.98 | MMP2 (0.80) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL18825042 | 0.98 | MMP2 (0.80) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL28099657 | 0.98 | MMP2 (0.80) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL16583 | 0.98 | MMP2 (0.80) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL6807467 | 0.96 | MMP2 (0.77) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL3475428 | 0.96 | MMP2 (0.77) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL352763 | 0.96 | MMP2 (0.77) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL4193755 | 0.96 | MMP2 (0.77) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL22032658 | 0.96 | MMP2 (0.77) | MMP2MMP9MMP3KMT2AMEN1 | |
| Phenobarbital SCHEMBL1322895 | 0.96 | MMP2 (0.77) | MMP2MMP9MMP3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-3884935-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-114404588-A | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-105979959-B | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3884935-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| CN-113383075-A | Method for determining the pH and calcium concentration or chlorine concentration in a sample | 芝加哥大学 | 2021-09-10 | — | — | CN | disclosed |
| US-20200038475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| EP-3532052-A1 | DESIGN AND COMPOSITION OF CELL-STABILIZED PHARMACEUTICAL FORMULATIONS | The Regents Of The University Of Michigan (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20190262453-A1 | DESIGN AND COMPOSITION OF CELL-STABILIZED PHARMACEUTICAL FORMULATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2019-08-29 | — | — | US | disclosed |
| WO-2010138851-A2 | E-CADHERIN AS A BIOMARKER OF GASTROESOPHAGEAL REFLUX DISEASE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-12-02 | — | — | WO | disclosed |
| US-7749491-B2 | Compounds and methods to enhance rAAV transduction | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080249050-A1 | Compounds and methods to enhance rAAV transduction | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2008-10-09 | — | — | US | disclosed |
| EP-1608763-A2 | COMPOUNDS AND METHODS TO ENHANCE RAAV TRANSDUCTION | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050037497-A1 | Compounds and methods to enhance rAAV transduction | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-02-17 | — | — | US | disclosed |
| WO-2004090145-A2 | COMPOUNDS AND METHODS TO ENHANCE RAAV TRANSDUCTION | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-0901663-A1 | SYSTEM AND METHOD FOR AUTOMATIC CRITICAL EVENT NOTIFICATION | Cedars-Sinai Medical Center (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997006499-A1 | SYSTEM AND METHOD FOR AUTOMATIC CRITICAL EVENT NOTIFICATION | CEDARS-SINAI MEDICAL CENTER (US) | 1997-02-20 | — | — | WO | disclosed |
| US-5374537-A | Administering organic or inorganic tetrahedral-shaped divalent oxy-anion | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1994-12-20 | — | — | US | disclosed |
| US-5189056-A | Decrease cell permeability; using sulfonates | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1993-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | MMP13 911/4885MMP8 1398/4885CACNA1F 1046/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | MMP13 911/4885MMP8 1398/4885CACNA1F 1046/4885 |
| US-20190262453-A1 | DESIGN AND COMPOSITION OF CELL-STABILIZED PHARMACEUTICAL FORMULATIONS | CALU, ABCG2, ACTB | MMP13 919/4885MMP8 2557/4885CACNA1F 3381/4885 |
| US-20200038475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | MMP13 911/4885MMP8 1398/4885CACNA1F 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.